52 recruiting, 45 completed, 31 active not recruiting, 23 not yet recruiting. 87 Phase 2, 50 Phase 3, 22 Not applicable, 14 Phase 1, 4 Phase 4.
Follow Androgen Antagonists: new trials by email Literature Review of Androgen Antagonists trials Research Report on Androgen Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-04 |
| Clinical Governance of Home Care and 30-Day Stability Integrated Home Care (ADI), Scheduled GP Home Care (ADP), Temporary Home Care (ADT) - Home Care Services, Quality of Health Care | Not yet recruiting | Azienda Sanitaria Locale BT | 500 | 2027-01-01 | 2026-10-27 | |
| Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitors (ARPIs) - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | University of Nebraska | 56 | 2026-12-24 | 2026-11-03 |
| RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | Georgetown University | 108 | 2026-12-01 | 2026-10-06 |
| A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India Darolutamide plus androgen deprivation therapy - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Not yet recruiting | Bayer | 60 | 2026-11-30 | 2026-10-20 | |
| Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT) Radiotherapy for MDT ± WPRT, Androgen Deprivation Therapy (ADT), Enzalutamide - Prostatic Neoplasms, Biochemical Recurrence | Phase 3 | Not yet recruiting | Ente Ospedaliero Cantonale, Bellinzona | 140 | 2026-11-01 | 2026-08-24 |
| A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer Deutenzalutamide Soft Capsules + ADT, Placebo + ADT - High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules | Phase 3 | Not yet recruiting | Hinova Pharmaceuticals Inc. | 1044 | 2026-10-31 | 2026-10-15 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| ITR-251 in Patients With Advanced Solid Tumors ITR-251, ITR-251 at RP2D, ARPI therapy - Solid Tumor Cancer, Castration Resistant Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | ITERIA BIOPHARMA, S.L. | 46 | 2026-10-01 | 2026-10-13 |
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs（apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | West China Hospital | 254 | 2026-09-15 | 2026-09-10 |
| Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer | Phase 2 | Recruiting | University of Nebraska | 140 | 2026-09-01 | 2026-10-19 |
| A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses - Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | 170 | 2026-09-01 | 2026-10-07 |
| Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cance | Phase 2 | Not yet recruiting | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | 50 | 2026-09-01 | 2026-07-21 |
| A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC) darolutamide plus androgen deprivation therapy, Enzalutamide plus androgen deprivation therapy - Metastatic Castration Sensitive Prostate Cancer (mCSPC) | Active not recruiting | Pfizer | 4700 | 2026-08-19 | 2026-10-06 | |
| Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer Androgen Deprivation Therapy (ADT), Radiotherapy - Prostate Cancer | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-08-06 | 2026-09-03 |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer INR731, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 208 | 2026-05-25 | 2026-10-23 |
| Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions), Androgen Deprivation Therapy (ADT) - Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy) | Not applicable | Recruiting | CHU de Quebec-Universite Laval | 434 | 2026-05-13 | 2026-07-01 |
| Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer Metastasis-directed radiotherapy, Rezvilutamide + ADT, Radical prostatectomy - Oligometastatic Prostate Cancer | Phase 2 | Not yet recruiting | Fudan University | 300 | 2026-05-01 | 2026-03-24 |
| Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer Dapagliflozin (10mg Tab), standard medical care (ADT + NHA) - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Recruiting | Yung NA | 68 | 2026-05-01 | 2026-10-28 |
Showing 20 of 182. Sign in to see all of them.
Prostatic Neoplasms (129) · Neoplasm Metastasis (12) · Adenocarcinoma (3) · Depression (3) · Depressive Disorder (3) · Depressive Disorder, Major (3) · Mental Disorders (3) · Mood Disorders (3) · Neoplasms (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Prostatic Diseases (2) · Radiation Injuries (2) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Erectile Dysfunction (1)
Bayer (7) · UNICANCER (6) · Fudan University (5) · Janssen Research & Development, LLC (5) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (5) · Novartis Pharmaceuticals (4) · Radiation Therapy Oncology Group (4) · German Oncology Center, Cyprus (3) · M.D. Anderson Cancer Center (3) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · University of Chicago (3) · University of Washington (3) · Affidea Nu-med Center of Oncological DIagnostics and Therapy (2) · Alliance for Clinical Trials in Oncology (2) · Anhui Medical University (2)
United States (79) · China (39) · Canada (25) · France (18) · Spain (15) · Australia (14) · Germany (14) · Italy (13) · Brazil (12) · Japan (12) · South Korea (12) · Poland (11) · Sweden (11) · United Kingdom (11) · Belgium (9)
Andrew McDonald, MD (2) · Michael Zelefsky, MD (2) · Abhinav Sidana, MD (1) · Abhishek Solanki, MD MS (1) · Adel Mandl (1) · Alison Tree, FRCR (1) · Alvaro A. Martinez, MD, FACR (1) · Amado J Zurita Saavedra (1) · Amar Kishan (1) · Amar Kishan, MD (1)
PMID 30508090, PMID 31577867, PMID 33270906, PMID 37099968, PMID 37656180, PMID 38421922, PMID 40607746, PMID 40645505, PMID 40852147, PMID 41055581, PMID 22747660, PMID 27208498, PMID 29384722, PMID 16000589, PMID 16425991, PMID 18407435, PMID 18990168, PMID 19826044, PMID 21799031, PMID 22452894, PMID 22771826, PMID 23306100, PMID 24210084, PMID 24423462, PMID 24590644, PMID 25420520, PMID 25592642, PMID 25708161, PMID 25981621, PMID 25995342, PMID 26244877, PMID 26301701, PMID 26301771, PMID 26718929, PMID 26719232, PMID 26858312, PMID 26980827, PMID 27068431, PMID 27155740, PMID 28159490, PMID 28300506, PMID 28578607, PMID 28578639, PMID 28760403, PMID 28844372, PMID 29042308, PMID 29240541, PMID 29261442, PMID 29326030, PMID 29522362
2023 (4), 2015 (2), 2025 (2), P30CA072720 (2), U10CA031946 (2), 2004 (1), 2017 (1), 2018 (1), 2019 (1), I01CX002277 (1), P30CA015704 (1), P30CA022453 (1), P30CA033572 (1), P30CA060553 (1), P50CA097186 (1)